Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Overview
Date Founded

1983

Headquarters

660 West Germantown Pike,Suite 110,Plymouth Meeting, PA 19462-1111

Type of Company

Public

Employees (Worldwide)

194

Industries

Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Contact Data
Trying to get in touch with decision makers at Inovio Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Financial & Accounting Officer

Chief Operating Officer & Executive Vice President

Chief Scientific Officer

Senior Vice President-Clinical Development

Senior Vice President, Regulatory Affairs

Senior Vice President-Clinical Development

Senior Vice President, Device Manufacturing Operations

Senior Vice President, Biological Manufacturing & Clinical Supply Management

Senior Vice President-Commercial

Board of Directors

Former Executive Vice President at Merck-Medco Managed Care LLC

Former President, Chief Executive Officer & Director at Aravive, Inc.

Founder at Inovio Pharmaceuticals, Inc.

Former Chief Financial Officer & Senior Vice President at MedImmune LLC

Former Senior Vice President, Human Resources at Merck & Co., Inc.

Former Vice President, Marketing at Sanofi

Executive Vice President at The Wistar Institute

Paths to Inovio Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Inovio Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Coatue Management manages client accounts in accordance with a long/short investment strategy. They invest primarily in US and non-US publicly traded equity securities and equity-related securities, such as equity swaps and options. The firm also invests in US and non-US private companies for certain clients. Coatue Management concentrates largely on certain sectors, including the global technology, media, telecommunications, and some healthcare and consumer sectors, and may also focus on companies in the mobile internet, cloud computing, machine learning, mobile gaming, user-generated content and aspects of the sharing economy and Chinese internet sectors. Their investment approach is based on fundamental research. They invest long and also engage in short selling for certain strategies.

Details Hidden

Bayesian Capital Management seeks to achieve superior risk-adjusted returns over a multi-year period by applying a statistically driven approach to global investing. The firm develops its investment strategies for its clients based primarily on statistical arbitrage. Bayesian Capital Management focuses on highly liquid equity securities, traded on exchanges or over the counter in US equity markets, which may be held long or sold short, for periods typically within a short-term to medium-term investment time frame, ranging from durations of several minutes to several months.

Details Hidden

Herzfeld is a global value investor. Portfolios are tailored to each individual's objectives and risk tolerance. They invest primarily in the stocks of small-cap companies in the consumer services, transportation and consumer non-durables sectors

Recent Transactions
Details Hidden

Inovio Pharmaceuticals, Inc. purchases GeneOne Life Science, Inc.

Details Hidden

Inovio Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Inovio Pharmaceuticals, Inc. purchases Bioject Medical Technologies, Inc.

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Professional

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants

Partner at Duane Morris LLP

Legal Advisor

Partner at Olshan Frome Wolosky LLP

Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conduct pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Key Stats and Financials As of 2019
Market Capitalization
$2.18B
Total Enterprise Value
$338M
Earnings Per Share
$-1.21
Revenue
$4.11M
Enterprise Value / Sales
82.13x
EBITDAMargin
-2,721.16%
EBITDA
$-112M
Total Equity
$5.4M
Total Debt
$99.5M
Net Profit
$-119M
TEVNet Income
-2.83x
Debt TEV
0.29x
Three Year Compounded Annual Growth Rate Of Revenue
-51.19%
Non-Profit Donations & Grants
$5,000 - $10K
2018
$2,500 - $4,999
2017
$10K - $25K
2017
Non-Profit Donations & Grants Received
Investments
Details Hidden

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Suppliers
University of Pennsylvania Computer Software | Philadelphia, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

GeneOne Life Science, Inc. Textiles | Seoul, South Korea

GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conduct pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals | Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Inovio Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Inovio Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Inovio Pharmaceuticals, Inc..